174 completed, 91 unknown, 75 terminated, 45 withdrawn. 183 Phase 2, 123 Phase 3, 75 Phase 1, 60 Phase 4, 45 Not applicable.
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Doxycycline Boosted Therapy in Lyme Borreliosis: DoBo Study. Hydroxychloroquin, Placebo, Doxycycline - Lyme Borreliosis, Nervous System | Phase 4 | Not yet recruiting | Radboud University Medical Center | 50 | 2027-03-01 | 2026-08-27 |
| ACT4RHD is an Open-label, Randomised, Adaptive Platform Trial to Evaluate Novel and Repurposed Clinical Interventions for Patients With Acute Rheumatic Fever and Carditis. ACT4RHD Seeks to Determine Whether These Interventions Reduce RHD Severity at 6 Months. Hydroxychloroquine (HCQ), No Hydroxychloroquine (HCQ), Prednisone or Prednisolone - Rheumatic Fever, Rheumatic Heart Disease in Children | Phase 3 | Not yet recruiting | Starship Child Health, Te Toka Tumai Auckland | 600 | 2026-12-01 | 2026-10-07 |
| Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants Azithromycin 250 mg x3/week (3 tablets/week), Prednisone 10 mg/day, Hydroxychloroquine 400 mg/day - Interstitial Lung Disease | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-11-01 | 2026-09-22 |
| Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks Topical anti-aging peptide serum - Aging | Early Phase 1 | Enrolling by invitation | Frontiers in Bioscience Research Institute and Aging | 48 | 2026-10-21 | 2026-10-22 |
| The Effect of Nicorandil on Rheumatoid Arthritis Patients Nicorandil Oral Tablet, Placebo, conventional synthetic antirheumatic drugs (cDMARDs) - Rheumatoid Arthritis (RA) | Phase 2 / Phase 3 | Recruiting | Ain Shams University | 70 | 2026-09-06 | 2026-09-16 |
| Pilot Study of Hydroxychloroquine for the Treatment of AIMSS Hydroxychloroquine Sulfate (HCQ) - Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain | Phase 2 | Not yet recruiting | Indiana University | 35 | 2026-09-01 | 2026-09-17 |
| Hydrochloroquinine & Decitabine With Venetoclax in AML Hydroxychloroquine, Venetoclax, Oral Decitabine/cedazuridine - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Rutgers, The State University of New Jersey | 18 | 2026-09-01 | 2026-09-10 |
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Rituximab Combining With Low-Dose Mycophenolate Mofetil on Proliferative Lupus Nephritis in Children rituximab, Mycophenolate Mofetil (MMF) Treatment, Cyclophosphamide - Lupus Nephritis | Not applicable | Not yet recruiting | Nanfang Hospital, Southern Medical University | 112 | 2026-06-01 | 2026-06-30 |
| A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus Dihydroartemisinin tablets, Hydroxychloroquine tablets - Discoid Lupus Erythematosus | Phase 2 | Not yet recruiting | Kunming Pharmaceuticals, Inc. | 100 | 2026-04-30 | 2026-04-30 |
| Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma Hydroxychloroquine, Lipiodol, Placebo - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 93 | 2026-04-01 | 2026-04-16 |
| Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma Tunlametinib, Pucotenlimab, Hydroxychloroquine (HC) - Melanoma Metastatic, NRAS Mutation | Phase 2 | Recruiting | Sun Yat-sen University | 37 | 2026-04-01 | 2026-08-10 |
| The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea Doxycycline, Hydroxychloroquine, Tofacitinib - Erythematotelangiectatic Rosacea | Not applicable | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 186 | 2026-02-01 | 2026-03-24 |
| HCQ in Resectable Localized Prostate Cancer Hydroxychloroquine Sulfate 400Mg Tab, Placebo - Resectable Localized Prostate Cancer | Early Phase 1 | Recruiting | Lionel.D.Lewis, MD | 20 | 2026-01-06 | 2026-02-04 |
| Autophagy Maintenance (AUTOMAIN) Hydroxychloroquine, Nelfinavir, Bevacizumab - Ovarian Cancer | Phase 2 | Recruiting | Medical University of South Carolina | 38 | 2025-12-18 | 2025-12-22 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial) Hydroxychloroquine (HCQ), Methotrexate (MTX) - Frontal Fibrosing Alopecia, Cicatricial Alopecia | Not yet recruiting | Erasmus Medical Center | 50 | 2025-11-01 | 2025-09-29 | |
| Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid, Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid - Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 474 | 2025-07-01 | 2025-07-11 |
| Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study Hydroxychloroquine Oral Tablet, Placebo oral tablet - IgA Nephropathy | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 334 | 2025-06-26 | 2026-10-09 |
Showing 20 of 457. Sign in to see all of them.
COVID-19 (162) · Coronavirus Infections (44) · Arthritis, Rheumatoid (33) · Severe Acute Respiratory Syndrome (13) · Pancreatic Neoplasms (11) · Pneumonia (11) · Breast Neoplasms (9) · Lupus Erythematosus, Systemic (9) · Pneumonia, Viral (8) · Colorectal Neoplasms (7) · Prostatic Neoplasms (7) · Respiratory Distress Syndrome (7) · Antiphospholipid Syndrome (6) · Carcinoma, Non-Small-Cell Lung (6) · Melanoma (6)
Abramson Cancer Center at Penn Medicine (16) · Rutgers, The State University of New Jersey (10) · Assistance Publique - Hôpitaux de Paris (9) · Assiut University (6) · Sanofi (6) · NYU Langone Health (5) · Qilu Hospital of Shandong University (5) · Shahid Beheshti University of Medical Sciences (5) · Brigham and Women's Hospital (4) · Cairo University (4) · M.D. Anderson Cancer Center (4) · Massachusetts General Hospital (4) · National Taiwan University Hospital (4) · Peking Union Medical College Hospital (4) · Tanta University (4)
United States (169) · China (43) · France (29) · Egypt (18) · Canada (17) · Brazil (16) · United Kingdom (13) · Netherlands (12) · Spain (11) · Italy (10) · Mexico (10) · Australia (8) · India (8) · Iran (8) · Pakistan (8)
Ravi Amaravadi, MD (6) · Seyed Sina Naghibi Irvani, MD, MPH, MBA (5) · Angela DeMichele, MD (3) · Ilad Alavi Darazam, MD (3) · Minoosh Shabani, MD (3) · Mohammadreza Haji Esmaelie, MD (3) · Sabine Hazan, MD (3) · Shervin Shokouhi, MD (3) · Sukeshi Patel Arora, MD (3) · Yunfeng Cheng (3) · Dan Vogl, MD (2) · DirkJan Hijnen, MD, PhD (2) · Frederico Toledo, MD (2) · Herbert Zeh, MD (2)
PMID 24254965, PMID 34473343, PMID 28416506, PMID 33570583, PMID 35288899, PMID 36695483, PMID 26429521, PMID 29929491, PMID 32091533, PMID 32109013, PMID 32492293, PMID 32673060, PMID 33204764, PMID 33394942, PMID 34013969, PMID 34350582, PMID 34519964, PMID 36734509, PMID 37162745, PMID 37489818, PMID 38104755, PMID 38299639, PMID 10632428, PMID 10648016, PMID 10649166, PMID 11824975, PMID 12090565, PMID 12719004, PMID 15366588, PMID 15590764, PMID 15688692, PMID 15803929, PMID 16368644, PMID 16499032, PMID 16716321, PMID 17075810, PMID 17487675, PMID 1750226, PMID 1757934, PMID 17825510, PMID 17885266, PMID 17925486, PMID 18667193, PMID 18945956, PMID 19390908, PMID 19439078, PMID 20447951, PMID 20528832, PMID 20561931, PMID 21112094
P30CA072720 (11), 2008 (2), 2015 (2), 2016 (2), 2017 (2), 2019 (2), P30CA060553 (2), U01CA132194 (2), 1ZIAHL002541-21 (1), 2009 (1), 2014 (1), 2018 (1), 2023 (1), 2025 (1), P30CA012197 (1)